Cargando…
Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
BACKGROUND AND AIM: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the current gold standard treatment for muscle-invasive urothelial bladder cancer (MIBC). Nonetheless, some MIBC patients showed limited pathological response after NAC. Herein, we used whole-exome sequencing (WES)...
Autores principales: | Yang, Zhao, Shen, Zongyi, Jin, Di, Zhang, Nan, Wang, Yue, Lei, Wanjun, Zhang, Zhiming, Chen, Haige, Naz, Faiza, Xu, Lida, Wang, Lei, Wang, Shihui, Su, Xin, Yu, Changyuan, Li, Chong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Whioce Publishing Pte. Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259609/ https://www.ncbi.nlm.nih.gov/pubmed/34239995 |
Ejemplares similares
-
Immune escape mechanisms and immunotherapy of urothelial bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021) -
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy
por: Yang, Zhao, et al.
Publicado: (2018) -
Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy
por: Qian, Hongyang, et al.
Publicado: (2022) -
Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015) -
Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)